FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.10  |  FHIR Version n/a  User: [n/a]

24644711000001104: Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 25-Jun 2014. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
80071101000001118 Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
80071201000001113 Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Has NHS dm+d (dictionary of medicines and devices) additional monitoring indicator EMA (European Medicines Agency) monitoring true Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Is a Umeclidinium bromide 65micrograms/dose / Vilanterol 22micrograms/dose dry powder inhaler 30 dose true Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Has AMP Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) true Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Has excipient Lactose false Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Has specific active ingredient Umeclidinium bromide false Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Has dispensed dose form Conventional release powder for inhalation true Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Legal category Prescription only medicine - legal category (qualifier value) true Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Discontinued indicator Never discontinued true Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Is a Actual medicinal product pack true Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Has specific active ingredient Vilanterol trifenatate false Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Has NHS dm+d (dictionary of medicines and devices) basis of strength substance Vilanterol false Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Has NHS dm+d (dictionary of medicines and devices) basis of strength substance Vilanterol true Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Has specific active ingredient Vilanterol trifenatate true Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Has specific active ingredient Umeclidinium bromide true Inferred relationship Existential restriction modifier
Anoro Ellipta 55micrograms/dose / 22micrograms/dose dry powder inhaler (GlaxoSmithKline UK Ltd) 30 dose Has basis of strength substance Vilanterol true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group

This concept is not in any reference sets

Back to Start